ERBB2 and cancer: For example, previous studies have shown that the introduction of the SV40 T/t common polypeptide increased the sensitivity of HER2-overexpressing cancer cells to chemotherapy drugs, and these reports have suggested that this is attributed to the inhibition of Bcl-2, Bcl-XL, and ERK by the polypeptide [54]–[56].